1. Home
  2. VIRT vs DFTX Comparison

VIRT vs DFTX Comparison

Compare VIRT & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Virtu Financial Inc.

VIRT

Virtu Financial Inc.

HOLD

Current Price

$57.71

Market Cap

5.1B

Sector

Finance

ML Signal

HOLD

Logo Definium Therapeutics Inc. Common Shares

DFTX

Definium Therapeutics Inc. Common Shares

N/A

Current Price

$42.14

Market Cap

5.9B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
VIRT
DFTX
Founded
2008
N/A
Country
United States
United States
Employees
N/A
106
Industry
Investment Bankers/Brokers/Service
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
5.1B
5.9B
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
VIRT
DFTX
Price
$57.71
$42.14
Analyst Decision
Hold
Strong Buy
Analyst Count
5
8
Target Price
$45.60
$38.50
AVG Volume (30 Days)
1.1M
1.8M
Earning Date
04-29-2026
05-04-2026
Dividend Yield
1.89%
N/A
EPS Growth
72.73
N/A
EPS
3.62
N/A
Revenue
$3,632,118,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.34
N/A
P/E Ratio
$29.51
N/A
Revenue Growth
26.25
N/A
52 Week Low
$31.55
$14.62
52 Week High
$68.02
$49.20

Technical Indicators

Market Signals
Indicator
VIRT
DFTX
Relative Strength Index (RSI) 46.27 52.63
Support Level $56.14 $16.37
Resistance Level $60.97 $45.42
Average True Range (ATR) 2.22 2.44
MACD -0.34 -0.84
Stochastic Oscillator 56.84 25.21

Price Performance

Historical Comparison
VIRT
DFTX

About VIRT Virtu Financial Inc.

Virtu Financial Inc is a financial firm that leverages technology to deliver liquidity to the world-wide markets and transparent trading solutions to its clients. The company's operating segment includes Market Making; and Execution Services. The non-operating segment of the company includes the Corporate segment. The company generates maximum revenue from the market-making segment. The Market Making segment principally consists of market-making in the cash, futures, and options markets across equities, options, fixed income, currencies, and commodities. Geographically, it derives a majority of its revenue from the United States and also has a presence in Ireland and Other Countries.

About DFTX Definium Therapeutics Inc. Common Shares

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.

Share on Social Networks: